PDCD1 and neoplasm: Immunotherapies consist of antibodies targeting immune checkpoint proteins (ICB), such as PD-1 (programmed cell death protein 1) on T cells and its ligand PD-L1 (programmed cell death 1 ligand 1) on antigen-presenting cells and tumor cells, that help tumor cells evade immune surveillance [58].